Chronic Obstructive Pulmonary Disease (COPD) Clinical Trial
Official title:
An Open Label, Partially Randomized, Four-period Study in Healthy Male Subjects to Investigate the Bioavailability and Pharmacokinetics of a Single Dose of AZD7594 When Administered Intravenously, Orally and Inhaled Via Two Different Dry Powder Inhalers (DPI) and a Pressurized Metered-dose Inhaler (pMDI)
Verified date | June 2016 |
Source | AstraZeneca |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This is an open-label,partially randomized, four-period study in healthy male subjects to assess the bioavailability and pharmacokinetics of a single dose of AZD7594 when administered intravenously, orally and inhaled via two different dry powder inhalers (DPIs) and a pressurized meter-dose inhaler (pMDI)
Status | Completed |
Enrollment | 21 |
Est. completion date | June 2016 |
Est. primary completion date | June 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: 1. Provision of signed and dated, written informed consent prior to any study specific procedures. 2. Healthy male subjects aged 18 - 45 years with suitable veins for cannulation or repeated venipuncture. 3. Have a body mass index (BMI) between 18 and 30 kg/m2, inclusive, and weigh at least 50 kg. 4. Subjects should be willing to follow reproductive restrictions to prevent pregnancy and drug exposure of a female partner and refrain from donating sperm or fathering a child from the first day of dosing until 3 months after the last dose of investigational product. 5. Be able to inhale from the dry powder inhaler (DPI) devices and the pressurized metered-dose inhaler (pMDI) device according to given instructions. Exclusion Criteria: 1. History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study. 2. History or presence of gastrointestinal (GI), hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs. 3. Any clinically significant illness, major medical/surgical procedure, or trauma within 4 weeks of the first administration of Investigational medicinal product (IMP). 4. Any clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results at screening and check-in, as judged by the investigator. 5. Any clinically significant abnormal findings in vital signs after a 5 minute rest at screening and check-in, as judged by the investigator, defined as any of the following: - Systolic blood pressure (BP) > 140 mm Hg; - Systolic BP < 90 mm Hg; - Diastolic BP > 90 mm Hg; - Diastolic BP < 60 mm Hg; or - Heart rate < 40 or > 85 beats per minute (bpm). 6. Any clinically significant abnormities in physical examination or lung function, as judged by the investigator. 7. Any clinically significant abnormalities on 12-lead electrocardiogram (ECG) at screening and check-in, as judged by the investigator. 8. Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG that may interfere with the interpretation of QTc (QT interval corrected) interval changes. This includes subjects with any of the following: - Clinically significant PR (PQ) (ECG interval measured from the onset of the P wave to the onset of the QRS complex) interval prolongation; - Intermittent or persistent second or third degree AV block; - Persistent or intermittent complete bundle branch block (BBB), incomplete bundle branch block (IBBB), or intraventricular conduction delay (IVCD) with QRS (ECG interval measured from the onset of the QRS complex to the J point) > 110 ms. Subjects with QRS > 110 ms but < 115 ms are acceptable if there is no evidence of, for example, ventricular hypertrophy or pre-excitation; or - Abnormal T wave morphology, particularly in the protocol defined primary lead. 9. Prolonged QTcF (QT interval corrected for heart rate using Fridericia's formula) > 450 msec or family history of long QT (ECG interval measured from the onset of the QRS complex to the end of the T wave) syndrome. 10. Known or suspected history of drug abuse, as judged by the investigator 11. Current smokers or those who have smoked or used nicotine products within the previous 3 months. 12. History of alcohol abuse or excessive intake of alcohol as judged by the investigator. 13. Positive screen for drugs of abuse, alcohol, and cotinine at screening or on each admission to the study center. 14. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to AZD7594 or to excipients. 15. Excessive intake of caffeine containing drinks e.g., coffee, tea, caffeine containing energy drinks and cola (in total no more than 3 cups per day). 16. Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks prior to the first administration of IMP. 17. Use of any prescribed or non-prescribed medication including vaccines, antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, vitamins and minerals during the 2 weeks prior to the first administration of IMP or longer if the medication has a long half-life. Occasional use of paracetamol/acetaminophen is allowed for minor pains and headaches (no more than 3000 mg/day). 18. Plasma donation within 1 month of screening or any blood donation/loss more than 500 mL during the 3 months prior to screening. 19. Has participated in a clinical study investigating clinical evaluation methods 1 month (or at least 5 half-lives) prior to the administration of investigational product. 20. Known Gilbert's syndrome, family history of Gilbert's syndrome or suspicion of Gilbert's syndrome based on liver function tests. 21. Any contraindication against the use of vagolytic or sympaticomimetic drugs, as judged by the investigator. 22. Involvement of any AstraZeneca, PAREXEL or study site employee or their close relatives. 23. Any positive result on screening for serum hepatitis B surface antigen (HBsAg), hepatitis C antibody and human immunodeficiency virus (HIV) antibody. 24. Judgment by the investigator that the subject should not participate in the study if they have any ongoing or recent (i.e., during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions and requirements. 25. Vulnerable subjects, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order. |
Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science
Country | Name | City | State |
---|---|---|---|
United States | Research Site | Baltimore | Maryland |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pharmacokinetics of AZD7594 delivered by Monodose inhaler and multiple-dose DPI or pMDI in terms of pulmonary bioavailability after inhalation (Fpulmonary) | Predose, 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours postdose | No | |
Secondary | Pharmacokinetics of AZD7594 following oral administration by assessment of the absolute systemic bioavailability after oral administration (Fpo) | Blood samples taken pre-dose and at 15, 30 and 45 minutes and 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose | No | |
Secondary | Pharmacokinetics of AZD7594 following inhalation by DPI1, DPI2 and pMDI inhaler by assessment of the absolute systemic bioavailability after inhalation (Finhalation, total) | Blood samples taken pre-dose and at 15, 30 and 45 minutes and 1, 2, 4, 6, 8, 12,16, 24, 36, 48 , 72 and 96 hours | No | |
Secondary | Safety profile of AZD7594 by assessment of the number of adverse events | From screening until the follow-up phone call, up to 10 weeks | Yes | |
Secondary | Pharmacokinetics of AZD7594 following i.v administration by assessment of the observed maximum plasma concentration(Cmax) | Blood samples taken pre-dose and at 5, 10, 15, 30 and 45 minutes and 1, 1.5, 2, 4, 6, 8, 12,16, 24, 36, 48, 72 and 96 hours post dose | No | |
Secondary | Pharmacokinetics of AZD7594 following i.v administration by assessment of the time to reach maximum plasma concentration (tmax) | Blood samples taken pre-dose and at 5, 10, 15, 30 and 45 minutes and 1, 1.5, 2, 4, 6, 8, 12,16, 24, 36, 48, 72 and 96 hours post dose | No | |
Secondary | Pharmacokinetics of AZD7594 following i.v administration by assessment of the area under the plasma concentration-curve from time zero to time of last quantifiable concentration (AUC0-t) | Blood samples taken pre-dose and at 5, 10, 15, 30 and 45 minutes and 1, 1.5, 2, 4, 6, 8, 12,16, 24, 36, 48, 72 and 96 hours post dose | No | |
Secondary | Pharmacokinetics of AZD7594 following i.v administration by assessment of the terminal rate constant, estimated by log-linear least squares regression of the terminal part of the concentration-time curve (?z) | Blood samples taken pre-dose and at 5, 10, 15, 30 and 45 minutes and 1, 1.5, 2, 4, 6, 8, 12,16, 24, 36, 48, 72 and 96 hours post dose | No | |
Secondary | Pharmacokinetics of AZD7594 following i.v administration by assessment of the terminal half-life (t½?z), estimated as (ln2)/ ?z | Blood samples taken pre-dose and at 5, 10, 15, 30 and 45 minutes and 1, 1.5, 2, 4, 6, 8, 12,16, 24, 36, 48, 72 and 96 hours post dose | No | |
Secondary | Pharmacokinetics of AZD7594 following i.v administration by assessment of the area under plasma concentration-time curve from time zero extrapolated to infinity (AUC) | Blood samples taken pre-dose and at 5, 10, 15, 30 and 45 minutes and 1, 1.5, 2, 4, 6, 8, 12,16, 24, 36, 48, 72 and 96 hours post dose | No | |
Secondary | Pharmacokinetics of AZD7594 following i.v administration by assessment of the mean absorption time (MAT) | Blood samples taken pre-dose and at 5, 10, 15, 30 and 45 minutes and 1, 1.5, 2, 4, 6, 8, 12,16, 24, 36, 48, 72 and 96 hours post dose | No | |
Secondary | Pharmacokinetics of AZD7594 following i.v administration by assessment of the mean residence time (MRT) | Blood samples taken pre-dose and at 5, 10, 15, 30 and 45 minutes and 1, 1.5, 2, 4, 6, 8, 12,16, 24, 36, 48, 72 and 96 hours post dose | No | |
Secondary | Pharmacokinetics of AZD7594 following i.v administration by assessment of the systemic clearance for parent drug estimated as dose divided by AUC (CL) | Blood samples taken pre-dose and at 5, 10, 15, 30 and 45 minutes and 1, 1.5, 2, 4, 6, 8, 12,16, 24, 36, 48, 72 and 96 hours post dose | No | |
Secondary | Pharmacokinetics of AZD7594 following i.v administration by assessment of the volume of distribution at terminal phase (Vz) | Blood samples taken pre-dose and at 5, 10, 15, 30 and 45 minutes and 1, 1.5, 2, 4, 6, 8, 12,16, 24, 36, 48, 72 and 96 hours post dose | No | |
Secondary | Pharmacokinetics of AZD7594 following i.v administration by assessment of the volume of distribution for parent drug at steady state (Vss) | Blood samples taken pre-dose and at 5, 10, 15, 30 and 45 minutes and 1, 1.5, 2, 4, 6, 8, 12,16, 24, 36, 48, 72 and 96 hours post dose | No | |
Secondary | Pharmacokinetics of AZD7594 following oral administration by assessment of the observed maximum plasma concentration (Cmax) | Blood samples taken pre-dose and at 15, 30 and 45 minutes and 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose | No | |
Secondary | Pharmacokinetics of AZD7594 following oral administration by assessment of the time to reach maximum plasma concentration (tmax) | Blood samples taken pre-dose and at 15, 30 and 45 minutes and 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose | No | |
Secondary | Pharmacokinetics of AZD7594 following oral administration by assessment of the area under the plasma concentration-curve from time zero to time of last quantifiable concentration (AUC0-t) | Blood samples taken pre-dose and at 15, 30 and 45 minutes and 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose | No | |
Secondary | Pharmacokinetics of AZD7594 following oral administration by assessment of the terminal rate constant, estimated by log-linear least squares regression of the terminal part of the concentration-time curve (?z) | Blood samples taken pre-dose and at 15, 30 and 45 minutes and 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose | No | |
Secondary | Pharmacokinetics of AZD7594 following oral administration by assessment of the terminal half-life (t½?z), estimated as (ln2)/ ?z | Blood samples taken pre-dose and at 15, 30 and 45 minutes and 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose | No | |
Secondary | Pharmacokinetics of AZD7594 following oral administration by assessment of the area under plasma concentration-time curve from time zero extrapolated to infinity (AUC) | Blood samples taken pre-dose and at 15, 30 and 45 minutes and 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose | No | |
Secondary | Pharmacokinetics of AZD7594 following oral administration by assessment of the mean absorption time (MAT) | Blood samples taken pre-dose and at 15, 30 and 45 minutes and 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose | No | |
Secondary | Pharmacokinetics of AZD7594 following oral administration by assessment of the mean residence time (MRT) | Blood samples taken pre-dose and at 15, 30 and 45 minutes and 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose | No | |
Secondary | Pharmacokinetics of AZD7594 following oral administration by assessment of the apparent total body clearance after extravascular administration (CL/F) | Blood samples taken pre-dose and at 15, 30 and 45 minutes and 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose | No | |
Secondary | Pharmacokinetics of AZD7594 following oral administration by assessment of the apparent volume of distribution for parent drug at terminal phase (Vz/F) | Blood samples taken pre-dose and at 15, 30 and 45 minutes and 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose | No | |
Secondary | Pharmacokinetics of AZD7594 following inhalation by DPI1, DPI2 and pMDI inhaler by assessment of the observed maximum plasma concentration (Cmax) | Blood samples taken pre-dose and at 15, 30 and 45 minutes and 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose | No | |
Secondary | Pharmacokinetics of AZD7594 following inhalation by DPI1, DPI2 and pMDI inhaler by assessment of the time to reach maximum plasma concentration (tmax) | Blood samples taken pre-dose and at 15, 30 and 45 minutes and 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose | No | |
Secondary | Pharmacokinetics of AZD7594 following inhalation by DPI1, DPI2 and pMDI inhaler by assessment of the area under the plasma concentration-curve from time zero to time of last quantifiable concentration (AUC0-t) | Blood samples taken pre-dose and at 15, 30 and 45 minutes and 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose | No | |
Secondary | Pharmacokinetics of AZD7594 following inhalation by DPI1, DPI2 and pMDI inhaler by assessment of the terminal rate constant, estimated by log-linear least squares regression of the terminal part of the concentration-time curve (?z) | Blood samples taken pre-dose and at 15, 30 and 45 minutes and 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose | No | |
Secondary | Pharmacokinetics of AZD7594 following inhalation by DPI1, DPI2 and pMDI inhaler by assessment of the terminal half-life (t½?z), estimated as (ln2)/ ?z | Blood samples taken pre-dose and at 15, 30 and 45 minutes and 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose | No | |
Secondary | Pharmacokinetics of AZD7594 following inhalation by DPI1, DPI2 and pMDI inhaler by assessment of the area under plasma concentration-time curve from time zero extrapolated to infinity (AUC) | Blood samples taken pre-dose and at 15, 30 and 45 minutes and 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose | No | |
Secondary | Pharmacokinetics of AZD7594 following inhalation by DPI1, DPI2 and pMDI inhaler by assessment of the mean absorption time (MAT) | Blood samples taken pre-dose and at 15, 30 and 45 minutes and 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose | No | |
Secondary | Pharmacokinetics of AZD7594 following inhalation by DPI1, DPI2 and pMDI inhaler by assessment of the mean residence time (MRT) | Blood samples taken pre-dose and at 15, 30 and 45 minutes and 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose | No | |
Secondary | Pharmacokinetics of AZD7594 following inhalation by DPI1, DPI2 and pMDI inhaler by assessment of the apparent total body clearance after extravascular administration (CL/F) | Blood samples taken pre-dose and at 15, 30 and 45 minutes and 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose | No | |
Secondary | Pharmacokinetics of AZD7594 following inhalation by DPI1, DPI2 and pMDI inhaler by assessment of the apparent volume of distribution for parent drug at terminal phase (Vz/F) | Blood samples taken pre-dose and at 15, 30 and 45 minutes and 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post dose | No | |
Secondary | Pharmacokinetics of AZD7594 following inhalation by DPI1, DPI2 and pMDI inhaler by assessment of the oral bioavailability after inhaled treatment (Foral) | Blood samples taken pre-dose and at 15, 30 and 45 minutes and 1, 2, 4, 6, 8, 12,16, 24, 36, 48 , 72 and 96 hours post dose | No | |
Secondary | Safety profile of AZD7594 by assessment of physical examinations | At screening | Yes | |
Secondary | Safety profile of AZD7594 by assessment of physical examinations | On Day -1 | Yes | |
Secondary | Safety profile of AZD7594 by assessment of physical examinations | On Day 5 | Yes | |
Secondary | Safety profile of AZD7594 by assessment of 12-lead electrocardiograms (ECGs) | At screening | Yes | |
Secondary | Safety profile of AZD7594 by assessment of 12-lead electrocardiograms (ECGs) | On Day 1 pre-dose until 5 hours 55 minutes post-dose | Yes | |
Secondary | Safety profile of AZD7594 by assessment of cardiac telemetry | At screening | Yes | |
Secondary | Safety profile of AZD7594 by assessment of cardiac telemetry | On Day 1 pre-dose until 6 hours post-dose | Yes | |
Secondary | Safety profile of AZD7594 by assessment of vital signs (blood pressure) | At screening | Yes | |
Secondary | Safety profile of AZD7594 by assessment of vital signs (pulse rate) | At screening | Yes | |
Secondary | Safety profile of AZD7594 by assessment of vital signs (oral temperature) | At screening | Yes | |
Secondary | Safety profile of AZD7594 by assessment of vital signs (blood pressure) | On Day 1 pre-dose and 0.25, 0.5, 1.0, 2.0, 4.0, 6.0, 12.0 and 24.0 hours post-dose | Yes | |
Secondary | Safety profile of AZD7594 by assessment of vital signs (oral temperature) | On Day 1 pre-dose and 0.25, 0.5, 1.0, 2.0, 4.0, 6.0, 12.0 and 24.0 hours post-dose | Yes | |
Secondary | Safety profile of AZD7594 by assessment of spirometry | At screening | Yes | |
Secondary | Safety profile of AZD7594 by assessment of spirometry | On Day 1 pre-dose and 30 and 60 minutes post-dose in Period 2 and Period 3 (maximum 14 days apart) | Yes | |
Secondary | Safety profile of AZD7594 by assessment of clinical laboratory assessments (hematology) | At screening | Yes | |
Secondary | Safety profile of AZD7594 by assessment of clinical laboratory assessments (clinical chemistry) | At screening | Yes | |
Secondary | Safety profile of AZD7594 by assessment of clinical laboratory assessments (urinalysis) | At screening | Yes | |
Secondary | Safety profile of AZD7594 by assessment of clinical laboratory assessments (hematology) | On Day -1 | Yes | |
Secondary | Safety profile of AZD7594 by assessment of clinical laboratory assessments (clinical chemistry) | On Day -1 | Yes | |
Secondary | Safety profile of AZD7594 by assessment of clinical laboratory assessments (urinalysis) | On Day -1 | Yes | |
Secondary | Safety profile of AZD7594 by assessment of taste (10 point rating scale for sweet, salty, sour, bitter, hot/spicy, metallic and overall taste) | On Day 1 post-dose in period 2 and Period 3 (maximum 14 days apart) | Yes | |
Secondary | Safety profile of AZD7594 by assessment of taste (fish taste, yes or no) | On Day 1 post-dose in Period 2 and Period 3 (maximum 14 days apart) | Yes | |
Secondary | Safety profile of AZD7594 by assessment of taste (does the medicine smell, yes or no) | On Day 1 post-dose in Period 2 and Period 3 (maximum 14 days apart) | Yes | |
Secondary | Safety profile of AZD7594 by assessment of taste (10 point rating scale for smell and the willingness to take the medicine again) | On Day 1 post-dose in Period 2 and Period 3 (maximum 14 days apart) | Yes | |
Secondary | Safety profile of AZD7594 by assessment of clinical laboratory assessments (hematology) | On Day 5 | Yes | |
Secondary | Safety profile of AZD7594 by assessment of clinical laboratory assessments (clinical chemistry) | On Day 5 | Yes | |
Secondary | Safety profile of AZD7594 by assessment of clinical laboratory assessments (urinalysis) | On Day 5 | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03282019 -
Study of Long-term HFNC for COPD Patients With HOT
|
N/A | |
Completed |
NCT05573464 -
A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
|
Phase 3 | |
Recruiting |
NCT06040086 -
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
|
Phase 3 | |
Not yet recruiting |
NCT06376994 -
Multi-Center Clean Air Randomized Controlled Trial in COPD
|
Phase 3 | |
Completed |
NCT02926534 -
Cross-Sectional Study of COPD Prevalence Among Smokers, Ex-smokers and Never-Smokers in Almaty, Kazakhstan
|
N/A | |
Completed |
NCT02728674 -
Management of Patients With Respiratory Symptoms in Sweden
|
N/A | |
Completed |
NCT02797392 -
Feasibility of a Preventive Program Against Lifestyle Related Diseases
|
N/A | |
Recruiting |
NCT02415478 -
Bronchioscopic Lung Volume Reduction (BLVR)
|
N/A | |
Completed |
NCT03487406 -
Anti-platelet Therapy in the Prevention of Cardiovascular Disease in Patients With COPD (APPLE-COPD: ICON 2)
|
Phase 2 | |
Completed |
NCT02518139 -
A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT02512510 -
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT02774226 -
Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT02459080 -
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Withdrawn |
NCT01908933 -
Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema
|
Phase 3 | |
Completed |
NCT01615484 -
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
|
N/A | |
Completed |
NCT01908140 -
Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT01893476 -
A Pragmatic Cluster Trial of a Tailored Intervention to Improve COPD Management
|
N/A | |
Completed |
NCT01701869 -
Microbiology & Immunology of the Chronically-inflamed Airway
|
N/A | |
Recruiting |
NCT02527486 -
Seoul National University Airway Registry
|
N/A | |
Withdrawn |
NCT01377428 -
Efficacy of Indacaterol 150 µg Versus Formoterol
|
Phase 4 |